Press Release – 04 April 17

04 April 17 – Enleofen Bio Pte. Ltd. was founded as a spin-out from National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical School with Series A funding. Enleofen develops first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Fibrotic disorders include diseases of the skin, lungs, heart, eye and kidneys and are a major health burden in Singapore and around the world. The initial discovery science and drug target validation was carried out at NHCS and Duke-NUS, funded by Professor Stuart Cook’ STAR award from the NMRC. Over five patent applications and a number of advanced antibody and inhibitor drug candidates arising from the scientific work have been licensed to the company giving it a significant head start in drug development. The company aims to have its lead antibody in clinical trials within a two year time frame with the goal of developing a drug that can be used to treat multiple diseases for which there are currently no treatment options.